TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multi-specific targeted peptide conjugate therapies for solid tumors, will present at Antibody Engineering & Therapeutics Europe 2026 in Basel, Switzerland, May 27–29, 2026.

Oral Presentation:
Title: Expanding the Reach of Targeted Cancer Therapy Using Multi-Specific Peptide-Drug Conjugates
Date and Time: Thursday, May 28, 2026, at 11:20 a.m. CEST
Invited Speaker: Caitlyn Miller, PhD, CEO & Co-Founder of TwoStep Therapeutics

TwoStep Therapeutics is a biotechnology company developing a pipeline built around a unique tumor-targeting polyspecific integrin-binding peptide (PIP) that can selectively bind several targets that are highly expressed on solid tumors. This multi-targeting feature enables the agent’s broad applicability to a wide range of tumor types and patient populations, overcoming the limitations of single-antigen targeting approaches. The company has leveraged this technology to create a pipeline of targeted cancer therapies for cytotoxic drug delivery and radioligand therapy.

More information: https://twosteptx.com/

Contact: media@twosteptx.com